Literature DB >> 3290182

Gram-positive infections in granulocytopenic patients: an important issue?

C Viscoli1, P Van der Auwera, F Meunier.   

Abstract

Gram-positive pathogens have become a common cause of bacteraemia in granulocytopenic cancer patients. This has been partially attributed to the use of central intravenous devices such as Hickman catheters; mucositis secondary to intensive antineoplastic chemotherapy or herpes infections may also be the source, especially for streptococci, whereas the skin is most probably the source for Staphylococcus epidermidis. Antimicrobial prophylaxis recommended mainly with the aim of reducing the incidence of Gram-negative bacillary infections may also play a significant role. The rate of response of documented infections caused by Gram-positive cocci to 'standard' empirical therapy (which has been mainly directed against Gram-negative bacilli) has been unsatisfactory although the lethality reported has been low. These results raise an important question, whether or not a specific anti-Gram-positive antibiotic such as vancomycin, should be added to the empirical regimen. A recent study suggested that empirical vancomycin provided no benefit since the mortality due to Gram-positive infections was low and a favourable outcome was obtained by adding a specific antibiotic after bacteriological documentation. However, others have shown that empirical use of vancomycin was associated with a more rapid resolution of fever. Vancomycin has been associated with an excess rate of side-effects and is difficult to administer. Another important question is whether or not antimicrobial prophylaxis for gut decontamination should include anti-Gram-positive cover. Recent studies have confirmed that Gram-negative bacillary bacteraemia may be prevented by oral gut decontamination but not bacteraemia due to Gram-positive bacteria.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3290182     DOI: 10.1093/jac/21.suppl_c.149

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents.

Authors:  K V Rolston; H T Nguyen; D H Ho; B LeBlanc; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

2.  Nosocomial bacteremia due to vancomycin-resistant Staphylococcus epidermidis in four patients with cancer, neutropenia, and previous treatment with vancomycin.

Authors:  V Krcmery; J Trupl; L Drgona; J Lacka; E Kukuckova; E Oravcova
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-03       Impact factor: 3.267

3.  Prophylaxis of bacterial infections with netilmicin and spiramycin in granulocytopenic patients.

Authors:  F Meunier; M Aoun; D Bron
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

4.  Ofloxacin versus trimethoprim-sulfamethoxazole for prevention of infection in patients with acute leukemia and granulocytopenia.

Authors:  W Kern; E Kurrle
Journal:  Infection       Date:  1991 Mar-Apr       Impact factor: 3.553

5.  Ex vivo study of serum bactericidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin.

Authors:  P Van der Auwera
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

6.  Pathogenicity and virulence of coagulase negative staphylococci in relation to adherence, hydrophobicity, and toxin production in vitro.

Authors:  C Molnàr; Z Hevessy; F Rozgonyi; C G Gemmell
Journal:  J Clin Pathol       Date:  1994-08       Impact factor: 3.411

Review 7.  Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients.

Authors:  P Van der Auwera; J Gérain
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  A prospective, randomized study of pefloxacin versus teicoplanin in the treatment of gram-positive coccal infections in cancer patients: early termination due to emergence of resistance to fluoroquinolones.

Authors:  M Aoun; P Van der Auwera; I Varthalitis; A M Bourguignon; M Janssen; D Daneau; F Meunier
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

9.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

10.  In vitro activity of decaplanin (M86-1410), a new glycopeptide antibiotic.

Authors:  M L Sanchez; R P Wenzel; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.